Cipla’s kidney cancer drug given nod by Delhi HC
New Delhi: The Delhi High Court today directed
the Drug Controller General of India to process the licence
application of Cipla for production and sale of generic
version of global pharma major Bayer Corporation`s liver and
kidney cancer drug `Nexavar`.
A division bench comprising Chief Justice A P Shah and
Justice Manmohan directed Drug Controller General of India
(DCGI) to take a decision over Cipla`s application.
"The government would process the application of Cipla
and would pass an order accordingly," said the court.
The court`s direction came over a petition filed by the
German pharma major Bayer, challenging an order of a single
bench, headed by Justice S Ravindra Bhatt, which rejected a
plea to restrain DCGI from granting lincence to Cipla to
produce and sale `Soranib`.
"We, prima facie agree with the order of the single
judge," the division bench said.
Meanwhile, the bench also said Cipla would have to take
the court`s permission before launching Soranib -- generic
version of Nexavar.
The court, however, added that licence granted by the
sectoral regulator would be the subject to its final decision
on the case.
It also declined Bayer`s plea to restrain the sectoral
regulator from taking any decision and directed all parties
including Bayer, Cipla and the government to file their
written submission in two weeks.